Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists Reply

被引：0

作者：

Mensah, Michael O. ^{[1
]}

Freitas, Daniel J. ^{[2
]}

Cartwright, Joseph R. ^{[3
]}

机构：

[1] Yale Univ, New Haven, CT 06520 USA

[2] San Francisco Dept Publ Hlth, San Francisco, CA USA

[3] Alameda Hlth Syst, Oakland, CA USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2024年 / 391卷 / 08期

关键词：

MORTALITY;

D O I：

10.1056/NEJMc2407932

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

To the Editor: The distribution framework for glucagon-like peptide-1 (GLP-1) receptor agonists proposed by Emanuel et al. in their Perspective article (May 30 issue)(1) considers potential years of life lost (PYLL) from obesity-related disease, but not race. How can clinicians and policymakers implement this framework "irrespective of factors such as race" (Table 1 in the article) when race and ethnic group are strongly associated with both PYLL and the risk of obesity-related disease? The PYLL metric - life expectancy minus the age at which a person dies - is seldom used in clinical medicine. But PYLL and life expectancy are . . .

引用

下载

页码：775 / 776

页数：2

共 50 条

[1] Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists
Emanuel, Ezekiel J.
Dellgren, Johan L.
Mccoy, Matthew S.
Persad, Govind
NEW ENGLAND JOURNAL OF MEDICINE, 2024, : 1839 - 1842
[2] GLP-1 and dual GIP/GLP-1 receptor agonists increase risk of aspiration
Reactions Weekly, 2025, 2044 (1) : 3 - 3
[3] Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Qiyuan Keith
FRONTIERS IN ENDOCRINOLOGY, 2024, 15
[4] Peripherally administered incretin peptides, including GIP, GLP-1 and a dual GIP/GLP-1 receptor agonists, activate several brain regions in anesthetised rats
Wilson, J. M.
Becerra, L.
Goetter, K.
Briley, K.
Novicki, A.
Cissell, D.
Smith, R. M.
Ai, M.
Emmerson, P. J.
Milicevic, Z.
Haupt, A.
Coskun, T.
DIABETOLOGIA, 2020, 63 (SUPPL 1) : S116 - S117
[5] GLP-1 and dual GIP/GLP-1 receptor agonists in overweight/obese patients for atherosclerotic cardiovascular disease prevention: Where are we now?
Muzurovic, Emir
Yumuk, Volkan Demirhan
Rizzo, Manfredi
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2023, 37 (12)
[6] The role of GLP-1/GIP receptor agonists in Alzheimer's disease
Yu, Chun Jiang
Ma, Dongying
Song, Ling Ling
Zhai, Zhen Nan
Tao, Ye
Zhang, Ying
Cai, Ling Yu
Hou, Ya Hui
Chen, Hong Yuan
Wang, Li
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 29 (06): : 661 - 668
[7] Tirzepatide: A Novel Dual GIP and GLP-1 Receptor Agonist
Wong, Elaine
JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2023, 19 (01):
[8] GLP-1 and GIP receptors co-agonists
Bernard, Elise S. C.
Metcalfe, Jacky
Sermadiras, Isabelle
Collinson, Andie
Naylor, Jacqueline
Hornigold, David
Bednarek, Maria A.
JOURNAL OF PEPTIDE SCIENCE, 2018, 24 : S143 - S143
[9] Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP-1, GIP receptor agonists, and dual agonists
Garvey, W. Timothy
Mahle, Cathy D.
Bell, Trevor
Kushner, Robert F.
OBESITY SCIENCE & PRACTICE, 2024, 10 (03):
[10] GLP-1 receptor agonists in NAFLD
Petit, J. -M.
Verges, B.
DIABETES & METABOLISM, 2017, 43 : 2S28 - 2S33

← 1 2 3 4 5 →